AAAAAA

   
Results: 1-24 |
Results: 24
Synergistic effects of the fenretinide (4-HPR) and anti-CD20 monoclonal antibodies on apoptosis induction of malignant human B cells
Authors: Shan, D Gopal, AK Press, OW
Citation: D. Shan et al., Synergistic effects of the fenretinide (4-HPR) and anti-CD20 monoclonal antibodies on apoptosis induction of malignant human B cells, CLIN CANC R, 7(8), 2001, pp. 2490-2495
Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease
Authors: Press, OW LeBlanc, M Lichter, AS Grogan, TM Unger, JM Wasserman, TH Gaynor, ER Peterson, BA Miller, TP Fisher, RI
Citation: Ow. Press et al., Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease, J CL ONCOL, 19(22), 2001, pp. 4238-4244
Pivotal study of iodine I 131 Tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas
Authors: Kaminski, MS Zelenetz, AD Press, OW Saleh, M Leonard, J Fehrenbacher, L Lister, TA Stagg, RJ Tidmarsh, GF Kroll, S Wahl, RL Knox, SJ Vose, JM
Citation: Ms. Kaminski et al., Pivotal study of iodine I 131 Tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas, J CL ONCOL, 19(19), 2001, pp. 3918-3928
Autologous stem cell transplantation for non-Hodgkin's lymphoma: comparison of radiation-based and chemotherapy-only preparative regimens
Authors: Gutierrez-Delgado, F Maloney, DG Press, OW Golden, J Holmberg, LA Maziarz, RT Hooper, H Buckner, CD Appelbaum, FR Bensinger, WI
Citation: F. Gutierrez-delgado et al., Autologous stem cell transplantation for non-Hodgkin's lymphoma: comparison of radiation-based and chemotherapy-only preparative regimens, BONE MAR TR, 28(5), 2001, pp. 455-461
Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and older
Authors: Gopal, AK Gooley, TA Golden, JB Maloney, DG Bensinger, WI Petersdorf, SH Appelbaum, FR Press, OW
Citation: Ak. Gopal et al., Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and older, BONE MAR TR, 27(6), 2001, pp. 593-599
A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts
Authors: Press, OW Corcoran, M Subbiah, K Hamlin, DK Wilbur, DS Johnson, T Theodore, L Yau, E Mallett, R Meyer, DL Axworthy, D
Citation: Ow. Press et al., A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts, BLOOD, 98(8), 2001, pp. 2535-2543
Response: Statistical designs for clinical trials of radioimmunotherapy
Authors: Gooley, T Storer, B Press, OW
Citation: T. Gooley et al., Response: Statistical designs for clinical trials of radioimmunotherapy, BLOOD, 98(4), 2001, pp. 1276-1276
Therapy of B-cell lymphomas with monoclonal antibodies and radioimmunoconjugates: the Seattle experience
Authors: Johnson, TA Press, OW
Citation: Ta. Johnson et Ow. Press, Therapy of B-cell lymphomas with monoclonal antibodies and radioimmunoconjugates: the Seattle experience, ANN HEMATOL, 79(4), 2000, pp. 175-182
Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells
Authors: Shan, DM Ledbetter, JA Press, OW
Citation: Dm. Shan et al., Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells, CANCER IMMU, 48(12), 2000, pp. 673-683
Molecular engineering of proteins and polymers for targeting and intracellular delivery of therapeutics
Authors: Stayton, PS Hoffman, AS Murthy, N Lackey, C Cheung, C Tan, P Klumb, LA Chilkoti, A Wilbur, FS Press, OW
Citation: Ps. Stayton et al., Molecular engineering of proteins and polymers for targeting and intracellular delivery of therapeutics, J CONTR REL, 65(1-2), 2000, pp. 203-220
Principles of radioimmunotherapy for hematologists and oncologists
Authors: Press, OW Rasey, J
Citation: Ow. Press et J. Rasey, Principles of radioimmunotherapy for hematologists and oncologists, SEMIN ONCOL, 27(6), 2000, pp. 62-73
Non-FcR-binding, humanized anti-CD3 antibody Hu291 induces apoptosis of human T cells more effectively than OKT3 and is immunosuppressive in vivo
Authors: Carpenter, PA Tso, JY Press, OW Yu, XZ Anasetti, C
Citation: Pa. Carpenter et al., Non-FcR-binding, humanized anti-CD3 antibody Hu291 induces apoptosis of human T cells more effectively than OKT3 and is immunosuppressive in vivo, TRANSPLAN P, 32(7), 2000, pp. 1545-1546
Physics for practitioners: The use of radiolabeled monoclonal antibodies in B-cell non-Hodgkin's lymphoma
Authors: Press, OW
Citation: Ow. Press, Physics for practitioners: The use of radiolabeled monoclonal antibodies in B-cell non-Hodgkin's lymphoma, SEM HEMATOL, 37(4), 2000, pp. 2-8
Non-Fc receptor-binding humanized anti-CD3 antibodies induce apoptosis of activated human T cells
Authors: Carpenter, PA Pavlovic, S Tso, JY Press, OW Gooley, T Yu, XZ Anasetti, C
Citation: Pa. Carpenter et al., Non-Fc receptor-binding humanized anti-CD3 antibodies induce apoptosis of activated human T cells, J IMMUNOL, 165(11), 2000, pp. 6205-6213
Really smart bioconjugates of smart polymers and receptor proteins
Authors: Hoffman, AS Stayton, PS Bulmus, V Chen, GH Chen, JP Cheung, C Chilkoti, A Ding, ZL Dong, LC Fong, R Lackey, CA Long, CJ Miura, M Morris, JE Murthy, N Nabeshima, Y Park, TG Press, OW Shimoboji, T Shoemaker, S Yang, HJ Monji, N Nowinski, RC Cole, CA Priest, JH Harris, JM Nakamae, K Nishino, T Miyata, T
Citation: As. Hoffman et al., Really smart bioconjugates of smart polymers and receptor proteins, J BIOMED MR, 52(4), 2000, pp. 577-586
Synergistic cytotoxicity of iodine-131-anti-CD20 monoclonal antibodies andchemotherapy for treatment of B-cell lymphomas
Authors: Johnson, TA Press, OW
Citation: Ta. Johnson et Ow. Press, Synergistic cytotoxicity of iodine-131-anti-CD20 monoclonal antibodies andchemotherapy for treatment of B-cell lymphomas, INT J CANC, 85(1), 2000, pp. 104-112
A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas
Authors: Press, OW Eary, JF Gooley, T Gopal, AK Liu, S Rajendran, JG Maloney, DG Petersdorf, S Bush, SA Durack, LD Martin, PJ Fisher, DR Wood, B Borrow, JW Porter, B Smith, JP Matthews, DC Appelbaum, FR Bernstein, ID
Citation: Ow. Press et al., A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas, BLOOD, 96(9), 2000, pp. 2934-2942
Emerging immunotherapies for non-Hodgkin lymphomas: The tortoise approaches the finish line
Authors: Press, OW
Citation: Ow. Press, Emerging immunotherapies for non-Hodgkin lymphomas: The tortoise approaches the finish line, ANN INT MED, 132(11), 2000, pp. 916-918
Hemolytic activity of pH-responsive polymer-streptavidin bioconjugates
Authors: Lackey, CA Murthy, N Press, OW Tirrell, DK Hoffman, AS Stayton, PS
Citation: Ca. Lackey et al., Hemolytic activity of pH-responsive polymer-streptavidin bioconjugates, BIOCONJ CHE, 10(3), 1999, pp. 401-405
Assessment of novel anti-p185(HER-2) monoclonal antibodies for internalization-dependent therapies
Authors: Park, JHM Yang, XW Park, JJ Press, OW Press, MF
Citation: Jhm. Park et al., Assessment of novel anti-p185(HER-2) monoclonal antibodies for internalization-dependent therapies, HYBRIDOMA, 18(6), 1999, pp. 487-495
Radiolabeled antibody therapy of B-cell lymphomas
Authors: Press, OW
Citation: Ow. Press, Radiolabeled antibody therapy of B-cell lymphomas, SEMIN ONCOL, 26(5), 1999, pp. 58-65
Clinical applications of anti-CD20 antibodies
Authors: Gopal, AK Press, OW
Citation: Ak. Gopal et Ow. Press, Clinical applications of anti-CD20 antibodies, J LA CL MED, 134(5), 1999, pp. 445-450
Characterization of scFv-Ig constructs generated from the anti-CD20 mAb 1F5 using linker peptides of varying lengths
Authors: Shan, DM Press, OW Tsu, TT Hayden, MS Ledbetter, JA
Citation: Dm. Shan et al., Characterization of scFv-Ig constructs generated from the anti-CD20 mAb 1F5 using linker peptides of varying lengths, J IMMUNOL, 162(11), 1999, pp. 6589-6595
Phase I study of I-131-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome
Authors: Matthews, DC Appelbaum, FR Eary, JF Fisher, DR Durack, LD Hui, TE Martin, PJ Mitchell, D Press, OW Storb, R Bernstein, ID
Citation: Dc. Matthews et al., Phase I study of I-131-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome, BLOOD, 94(4), 1999, pp. 1237-1247
Risultati: 1-24 |